Skip to main content

ASO Visual Abstract: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers

This is a preview of subscription content, access via your institution.

Funding

This work was funded by a grant from the Athena Foundation. This study was presented in poster format at the Society of Surgical Oncology 2022 International Conference on Surgical Cancer Care, 9–12 March 2022, Houston, TX.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meghan R. Flanagan MD, MPH, FACS.

Ethics declarations

Disclosures

C.H. is a former employee and current stockholder of Color Genomics. H.H.C. discloses research funds to institution from Clovis Oncology, Color Genomics, Janssen, Medivation, Phosplatin, and Sanofi, consultant for AstraZeneca, and royalties from UpToDate. J.G.S. discloses scientific advisory board of Teryx. The other authors have nothing to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Clark, N.M., Roberts, E.A., Federenko, C. et al. ASO Visual Abstract: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. Ann Surg Oncol 30, 1329–1330 (2023). https://doi.org/10.1245/s10434-022-12800-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12800-w